Drug intelligence / Profile preview

Anti-SARS-CoV-2 siRNA-MNM

Development stage: Unknown
Lead developer: Interna Therapeutics
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intranasal

Overview

Anti-SARS-CoV-2 siRNA-MNM is an intranasally administered small interfering RNA (siRNA) therapeutic being developed by Interna Therapeutics for the treatment of COVID-19. The drug utilizes Interna's proprietary MNM (Modified Nucleoside-containing Micelle) delivery technology, which is designed to protect the siRNA from degradation and enhance cellular uptake. By targeting a highly conserved sequence within the SARS-CoV-2 genome, the siRNA triggers the RNA interference (RNAi) pathway to degrade viral RNA and inhibit viral replication. This approach is intended to provide a broad-spectrum antiviral effect against various SARS-CoV-2 variants. The candidate is currently in Phase 1 clinical development.

Targets

SARS-CoV-2 RNA

Beyond the preview

Go deeper on Anti-SARS-CoV-2 siRNA-MNM.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anti-SARS-CoV-2 siRNA-MNM.

Explore the full profile